Strathfield

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

Researchers are studying the safety and how well different doses of FWY003 work in people with geographic atrophy (GA) caused by age-related macular degeneration (AMD). This Phase 2 study aims to understand the relationship between the dose of FWY003 and its effects compared to a placebo. The study is randomized, multi-center, and double-masked, ensuring that neither participants nor researchers know who receives the drug or placebo. Participants will be assigned to receive either FWY003 at specific doses or a placebo. The study is designed to find the best dose by comparing the effects of FWY003 against placebo in patients with GA secondary to AMD. Treatments will be given according to the study protocol, and the response to different doses will be monitored to assess both efficacy and safety. During the study, participants will be evaluated for changes in the size of their GA lesions from the start of the study to month 18. Eye examinations and imaging will be used to monitor the lesion area and vision status. Safety will be closely observed throughout the study, with regular check-ups and assessments to monitor any side effects or changes in eye health.

Researchers are evaluating a treatment for adults aged 50 and older who have macular neovascularization caused by neovascular age-related macular degeneration (nAMD). This Phase 3 trial compares a single intravitreal injection of 4D-150 with the active control treatment EYLEA (aflibercept). The study aims to assess changes in visual acuity over one year to better understand the effects of these treatments on this eye condition. Participants are randomly assigned to receive either a single dose of 4D-150 injected into the eye on Day 1 or ongoing EYLEA injections at scheduled visits. The study includes adults who have either never received anti-VEGF therapy or have had up to four prior anti-VEGF injections with documented improvement. The condition must be active and confirmed by specialized eye imaging tests before enrollment. Throughout the 52-week study, participants will have regular assessments including vision tests measured by the ETDRS letter score, eye imaging, and clinical evaluations to monitor treatment effects and safety. Researchers will track visual acuity changes from the start of treatment and watch for any adverse effects. The study's main goal is to measure the average change in best corrected visual acuity at one year.